Stock listing
Stuttgart:6UI Arecor Therapeutics PLC Aktie
German listing (Stuttgart) of Arecor Therapeutics PLC · home listing LSE:AREC
Follow Arecor Therapeutics PLC into a list and get an email when it puts out news.
Home listing price · LSE:AREC
71.50p GBX (pence) -6.00 (-7.7%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, LSE:AREC
- Day range
- 70.00p – 76.38p GBX (pence)Nov 20, 2026
- Volume
- 19,465 sharesNov 20, 2026
- Market cap
- £32.39M GBPAt the close on Nov 20, 2026 · price × 45.30M shares outstanding
- 52-week range
- 55.27p – 95.00p GBX (pence)Lowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- £17,125 GBPMedian day 11,751 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| LSE:AREC · Home | 71.50p GBX (pence) | -6.00 (-7.7%) | 19,465 | 76.00p | 76.38p | 70.00p | 77.50p | Close on Nov 20, 2026 |
| Frankfurt:6UI | €0.755 EUR | -0.055 (-6.8%) | — | €0.680 | €0.775 | €0.680 | €0.810 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · LSE:AREC · GBX (pence), adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| 71.50p | -6.00 | -7.7% | 76.00p | 76.38p | 70.00p | 19,465 | |
| 77.50p | 0.00 | 0.0% | 77.50p | 77.50p | 77.00p | 6,493 | |
| 77.50p | 0.00 | 0.0% | 77.50p | 77.50p | 75.00p | 45 | |
| 77.50p | 0.00 | 0.0% | 77.50p | 77.50p | 75.00p | 8,208 | |
| 77.50p | 0.00 | 0.0% | 78.00p | 78.00p | 75.10p | 57,039 | |
| 77.50p | 0.00 | 0.0% | 80.00p | 80.00p | 75.00p | 50 | |
| 77.50p | 0.00 | 0.0% | 75.00p | 78.00p | 75.00p | 3,393 | |
| 77.50p | 0.00 | 0.0% | 76.00p | 81.50p | 76.00p | 2,100 | |
| 77.50p | 0.00 | 0.0% | 77.50p | 78.15p | 75.00p | 7,958 | |
| 77.50p | 0.00 | 0.0% | 77.50p | 78.40p | 77.00p | 6,230 | |
| 77.50p | 0.00 | 0.0% | 77.50p | 80.00p | 77.50p | 87 | |
| 77.50p | -5.00 | -6.1% | 80.00p | 80.00p | 77.50p | 7,863 | |
| 82.50p | 0.00 | 0.0% | 82.50p | 85.00p | 82.00p | 3,173 | |
| 82.50p | 0.00 | 0.0% | 83.45p | 85.00p | 82.00p | 3,216 | |
| 82.50p | 0.00 | 0.0% | 82.50p | 83.45p | 81.50p | 330 | |
| 82.50p | 0.00 | 0.0% | 83.45p | 83.45p | 81.50p | 564 | |
| 82.50p | 0.00 | 0.0% | 81.25p | 84.00p | 81.25p | 22,423 | |
| 82.50p | 0.00 | 0.0% | 82.50p | 85.00p | 82.50p | 25 | |
| 82.50p | 0.00 | 0.0% | 82.50p | 85.00p | 81.25p | 1,459 | |
| 82.50p | 0.00 | 0.0% | 82.50p | 85.00p | 81.25p | 1,459 | |
| 82.50p | 0.00 | 0.0% | 82.50p | 82.85p | 82.50p | 1,810 | |
| 82.50p | 0.00 | 0.0% | 82.50p | 85.00p | 82.50p | 25,598 | |
| 82.50p | 0.00 | 0.0% | 82.50p | 86.00p | 82.50p | 39,329 | |
| 82.50p | 0.00 | 0.0% | 82.50p | 83.45p | 80.10p | 6,461 | |
| 82.50p | 0.00 | 0.0% | 82.50p | 84.00p | 81.00p | 83,875 | |
| 82.50p | +2.50 | +3.1% | 82.50p | 85.00p | 80.00p | 48,628 | |
| 80.00p | +5.00 | +6.7% | 75.00p | 80.00p | 72.00p | 19,112 | |
| 75.00p | 0.00 | 0.0% | 75.00p | 80.00p | 75.00p | 11,505 | |
| 75.00p | +2.50 | +3.4% | 72.50p | 80.00p | 71.00p | 58,831 | |
| 72.50p | 0.00 | 0.0% | 72.50p | 73.60p | 72.50p | 73,351 | |
| 72.50p | 0.00 | 0.0% | 72.50p | 75.00p | 71.31p | 53,294 | |
| 72.50p | 0.00 | 0.0% | 72.50p | 75.00p | 71.25p | 28,064 | |
| 72.50p | 0.00 | 0.0% | 72.50p | 75.00p | 71.00p | 1,009 | |
| 72.50p | 0.00 | 0.0% | 72.50p | 75.00p | 71.80p | 39,120 | |
| 72.50p | 0.00 | 0.0% | 72.50p | 75.00p | 70.00p | 29,203 | |
| 72.50p | 0.00 | 0.0% | 72.50p | 75.00p | 71.00p | 30,323 | |
| 72.50p | -16.00 | -18.1% | 72.50p | 75.00p | 71.00p | 94,553 | |
| 88.50p | 0.00 | 0.0% | 88.50p | 90.00p | 87.00p | 64,951 | |
| 88.50p | 0.00 | 0.0% | 88.50p | 88.50p | 87.00p | 23,501 | |
| 88.50p | 0.00 | 0.0% | 88.50p | 90.00p | 87.55p | 14,842 | |
| 88.50p | 0.00 | 0.0% | 88.50p | 89.70p | 87.00p | 12,251 | |
| 88.50p | +1.00 | +1.1% | 87.73p | 90.00p | 87.73p | 31,862 | |
| 87.50p | 0.00 | 0.0% | 87.50p | 89.90p | 85.00p | 12,801 | |
| 87.50p | +1.50 | +1.7% | 86.08p | 90.00p | 86.08p | 11,751 | |
| 86.00p | 0.00 | 0.0% | 86.00p | 90.00p | 83.00p | 6,979 | |
| 86.00p | +0.50 | +0.6% | 86.00p | 86.00p | 85.26p | 1,182 | |
| 85.50p | +4.50 | +5.6% | 81.00p | 85.50p | 77.00p | 23,735 | |
| 81.00p | 0.00 | 0.0% | 81.00p | 85.00p | 77.00p | 79,713 | |
| 81.00p | 0.00 | 0.0% | 81.00p | 85.00p | 77.00p | 10,716 | |
| 81.00p | +3.50 | +4.5% | 77.50p | 85.00p | 75.00p | 12,705 | |
| 77.50p | 0.00 | 0.0% | 77.50p | 79.70p | 77.50p | 8,132 | |
| 77.50p | 0.00 | 0.0% | 77.50p | 79.90p | 77.10p | 10,644 | |
| 77.50p | 0.00 | 0.0% | 77.50p | 80.00p | 75.00p | 40,019 | |
| 77.50p | +1.00 | +1.3% | 76.55p | 80.00p | 76.55p | 43,023 | |
| 76.50p | +2.50 | +3.4% | 74.96p | 77.00p | 74.96p | 14,817 | |
| 74.00p | 0.00 | 0.0% | 74.00p | 74.80p | 73.00p | 8,449 | |
| 74.00p | 0.00 | 0.0% | 74.00p | 74.80p | 73.61p | 1,507 | |
| 74.00p | 0.00 | 0.0% | 74.00p | 74.80p | 73.51p | 57,296 | |
| 74.00p | +5.50 | +8.0% | 68.50p | 74.50p | 68.23p | 75,524 | |
| 68.50p | +2.50 | +3.8% | 66.00p | 70.00p | 65.00p | 34,552 | |
| 66.00p | 0.00 | 0.0% | 66.00p | 67.00p | 65.61p | 9,469 | |
| 66.00p | 0.00 | 0.0% | 66.00p | 67.00p | 65.00p | 2,650 | |
| 66.00p | 0.00 | 0.0% | 66.00p | 66.00p | 65.00p | 3,797 | |
| 66.00p | +2.50 | +3.9% | 66.00p | 66.90p | 66.00p | 1,494 | |
| 63.50p | +2.50 | +4.1% | 62.84p | 67.00p | 62.84p | 16,721 |
- Ticker
- Stuttgart:6UI
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Stuttgart
- Currency
- EUR
What changed lately
Latest news release · Oct 15, 2026
Patents for concentrated ultra-rapid insulins
Latest earnings call · Oct 12, 2026
Arecor Therapeutics (LSE:AREC) — Half Year esults for the six months to 30 June 2026
Replay and transcript
Latest deck · Oct 12, 2026
H1 2026 Earnings Presentation
Earnings · 21 slides
Latest news
Patents for concentrated ultra-rapid insulins
Oct 15, 2026
Closed 82.50p (+3.1%) on Oct 15, 2026
Holding(s) in Company
Oct 13, 2026
Closed 75.00p (0.0%) on Oct 13, 2026
Half Year Results Investor Presentation
Oct 8, 2026
Closed 72.50p (0.0%) on Oct 8, 2026
Result of Retail Offer
Oct 7, 2026
Closed 72.50p (0.0%) on Oct 8, 2026
Retail Offer to raise up to £130,000
Sep 30, 2026
Closed 72.50p (-18.1%) on Sep 30, 2026
Results of Placing
Sep 30, 2026
Closed 72.50p (-18.1%) on Sep 30, 2026
Close of Accelerated Bookbuild to New Orders
Sep 30, 2026
Closed 72.50p (-18.1%) on Sep 30, 2026
Proposed Fundraising to raise up to £5.13 million
Sep 30, 2026
Closed 72.50p (-18.1%) on Sep 30, 2026
Interim results for the six months to 30 June 2026
Sep 30, 2026
Closed 72.50p (-18.1%) on Sep 30, 2026
AT278 data published in peer-reviewed journal
Aug 13, 2026
Closed 59.50p (0.0%) on Aug 13, 2026
Arecor Therapeutics PLC on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 23 in the last 12 months · 155 in all · newest Oct 15, 2026 · oldest 2021
- Calls
- 9 calls with a replay · 9 with a transcript · latest Oct 12, 2026
- Decks
- 12 decks · latest Oct 12, 2026
Where Arecor Therapeutics PLC is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| LSE:AREC · Home listing | LSE | United Kingdom | GBX |
| LS Exchange:A3CRY2 | LS Exchange | Germany | EUR |
| Lang & Schwarz:A3CRY2 | Lang & Schwarz | Germany | EUR |
| Dusseldorf:6UI | Dusseldorf | Germany | EUR |
| Stuttgart:6UI · This page | Stuttgart | Germany | EUR |
| Frankfurt:6UI | Frankfurt | Germany | EUR |
Valuation
EV/sales 17.1× against a median of 20.0×: 2nd lowest of 4 Biotechnology companies shown. Statements: Year to Dec 31, 2025 · balance Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- £29.29M GBP
- P/E
- 48.8×
- EV/sales
- 17.1×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 8.8×
- Gross margin
- 61.3%
- Operating margin
- −272.2%
- Net margin
- 38.7%
- Debt to equity
- 0.0×
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Arecor Therapeutics PLC · LSE:AREC | US$42.37M | US$38.32M | 48.8× | 17.1× | n/a | 8.8× | 38.7% | 0.0× | n/a |
| Spero Therapeutics, Inc. · NASDAQ:SPRO | US$43.23M | −US$63.10M | n/a | −1.5× | n/a | 55.4× | −71.0% | 2.0× | 1.68 |
| Eloxx Pharmaceuticals, Inc. · NASDAQ:ELOX | US$43.15M | −US$1.28M | n/a | n/a | n/a | 1.1× | n/a | 0.3× | n/a |
| Corbus Pharmaceuticals Holdings, Inc. · NASDAQ:CRBP | US$42.45M | −US$68.98M | n/a | n/a | n/a | 0.5× | n/a | 0.1× | 1.85 |
| OS Therapies Incorporated · AMEX:OSTX | US$42.00M | US$41.57M | n/a | n/a | n/a | n/a | n/a | n/a | 1.70 |
| Advagene Biopharma Co., Ltd. · TPEX:6709 | US$41.88M | US$32.02M | n/a | n/a | n/a | 3.9× | n/a | 0.0× | n/a |
| Biomea Fusion, Inc. · NASDAQ:BMEA | US$41.75M | US$15.85M | n/a | n/a | n/a | 5.5× | n/a | 0.1× | 1.14 |
| Prescient Therapeutics Limited · ASX:PTX | US$41.64M | US$35.80M | n/a | n/a | n/a | 4.4× | n/a | 0.0× | n/a |
| Mereo BioPharma Group plc · NASDAQ:MREO | US$41.52M | US$16.00M | n/a | 20.0× | n/a | 1.8× | n/a | 0.0× | 1.34 |
| Elicio Therapeutics, Inc. · NASDAQ:ELTX | US$41.05M | US$19.78M | n/a | n/a | n/a | 2.2× | n/a | 0.5× | 1.81 |
| MiNK Therapeutics, Inc. · NASDAQ:INKT | US$40.93M | US$33.46M | n/a | 167× | n/a | n/a | n/a | n/a | 0.81 |
| Median of the others | US$41.82M | US$17.89M | 20.0× | 3.0× | −71.0% | 0.1× | 1.68 |
Forecasts
Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.
- Price target
- 250.50 GBX · Analysts' mean
- EPS, year to Dec 2026
- -0.13 · 2 analysts
- Revenue, year to Dec 2026
- 300K · 2 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Sarah Howell | Chief Executive Officer and Executive Director |
| David Ellam | Chief Financial Officer and Executive Director |
| Arecor Therapeutics | Singer Capital Markets Advisory LLP |
| Phil Davies | Singer Capital Markets Advisory LLP |
| David Gerring | Chief Development Officer |
| Jan Jezek | Chief Scientific Officer |
Board
| Director | Role |
|---|---|
| Andrew Richards | Non-Executive Chair and Chair of the Nomination Committee |
| David Ellam | Chief Financial Officer and Executive Director |
| Jeremy Morgan | Non-Executive Director and Chair of the Remuneration Committee |
| Sam Fazeli | Non-Executive Director |
| Sarah Howell | Chief Executive Officer and Executive Director |
| Simon Ormiston | Non-Executive Director and Chair of the Audit & Risk Committee |
Events
Calls
| Call | When | Status |
|---|---|---|
| Arecor Therapeutics (LSE:AREC) — Half Year esults for the six months to 30 June 2026 | Mon, Oct 12, 2026 · 9:00 AM ET | Replay |
| Arecor Therapeutics (LSE:AREC) Q4 2025 Earnings Call | Thu, Apr 23, 2026 · 6:00 AM ET | Replay |
| Arecor Therapeutics (LSE:AREC) — Arecor Interim Results, Co-development Agreement & Sale of Royalty and Technology Access Fees | Thu, Oct 02, 2025 · 6:00 AM ET | Replay |
| Arecor Therapeutics (LSE:AREC) — Final Results Results for the year ended 31 December 2024 | Thu, May 01, 2025 · 9:00 AM ET | Replay |
| Arecor Therapeutics (LSE:AREC) — Interim Results | Thu, Oct 03, 2024 · 10:00 AM ET | Replay |
| Arecor Therapeutics (LSE:AREC) — Investor Presentation | Wed, Sep 20, 2023 · 9:00 AM ET | Replay |
| Arecor Therapeutics (LSE:AREC) — Results | Wed, Apr 26, 2023 · 9:00 AM ET | Replay |
| Arecor Therapeutics (LSE:AREC) — Investor Presentation | Thu, Aug 04, 2022 · 5:00 AM ET | Replay |
| Arecor Therapeutics (LSE:AREC) — Year End Results | Thu, May 05, 2022 · 5:00 AM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q2 2025 | Sep 25, 2025 | +19.3% |
| Quarter to Mar 31, 2025 | May 6, 2025 | 0.0% |
| Q1 2023 | Apr 20, 2023 · Before open | 0.0% |
| Q2 2022 | Sep 8, 2022 · Before open | 0.0% |
| Q1 2022 | Apr 25, 2022 · Before open | 0.0% |
| Q2 2021 | Sep 23, 2021 · Before open | +2.3% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| H1 2026 Earnings Presentation | Earnings | 21 slides | Oct 12, 2026 |
| Investor Presentation (October 2026) | Investor deck | 30 slides | October 2026 |
| Investor Presentation (June 2026) | Investor deck | 30 slides | June 2026 |
| FY2025 Earnings Presentation | Earnings | 34 slides | Apr 23, 2026 |
| FY2025 Earnings Presentation | Earnings | 34 slides | Apr 13, 2026 |
| FY2024 Earnings Presentation | Earnings | 21 slides | Apr 22, 2025 |
| H1 2024 Earnings Presentation | Earnings | 23 slides | Sep 26, 2024 |
| FY2023 Earnings Presentation | Earnings | 25 slides | May 16, 2024 |
| H1 2023 Earnings Presentation | Earnings | 22 slides | Sep 14, 2023 |
| FY2022 Earnings Presentation | Earnings | 26 slides | April 2023 |
All 12 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| FY2021 Earnings Presentation | Earnings | 23 slides | Apr 25, 2022 |
| H1 2021 Earnings Presentation | Earnings | 21 slides | Sep 23, 2021 |
Financings
| Raise | Date | In US dollars |
|---|---|---|
| New ordinary shares (Retail Offer Shares) Closed: £130,000 raised · GBX 68 a share · Singer Capital Markets +1 Dealers: Singer Capital Markets (lead), Singer Capital Markets Securities Limited Use of proceeds: General working capital and to strengthen the Group's balance sheet | Oct 7, 2026 | US$171,735 |
| Private placement of new ordinary shares Update: about £5M · GBX 68 a share · Singer Capital Markets Dealers: Singer Capital Markets (lead) Use of proceeds: Strengthen balance sheet, extend cash runway to December 2027 and fund critical-path insulin development activities | Sep 30, 2026 | US$6.61M |
| Royalty financing with warrants over ordinary shares Announced: up to US$11M · Warrants at GBX 67.39 for 120 months Buyers: Ligand Pharmaceuticals Inc. (royalty financing of up to $11 million; warrants over 1,002,739 ordinary shares); Ligand (pays up to $11.0 million for royalty and fee rights and receives warrants over 1,002,739 ordinary shares); Ligand Pharmaceuticals Incorporated (pays up to $11.0 million for royalty rights and receives warrants over 1,002,739 ordinary shares) Use of proceeds: Start AT278 Phase 2-enabling activities and extend cash runway to 1H 2027 | Sep 25, 2025 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in GBP
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.71M | 5.05M | 4.57M | 2.40M | 1.16M | 1.70M | 1.89M | 747.7K | 1.35M |
| Cost of revenue | 663.0K | 3.51M | 3.32M | 341.0K | |||||
| Gross profit | 1.05M | 1.54M | 4.57M | 2.40M | 1.16M | 1.70M | 1.89M | 747.7K | 1.35M |
| Research and development | 2.69M | 3.04M | 5.98M | 8.61M | 5.39M | 3.94M | 3.56M | 3.09M | 2.33M |
| Selling, general and administrative | 3.17M | 6.18M | 8.91M | 5.55M | 2.39M | 1.64M | 1.61M | 1.42M | 1.00M |
| Operating income | -4.67M | -10.7M | -9.18M | -11.7M | -5.98M | -3.43M | -2.69M | -2.85M | -1.40M |
| Depreciation and amortization | 215.0K | 446.0K | 496.0K | 341.0K | 171.0K | 168.0K | 151.5K | 166.9K | 172.9K |
| EBITDA | -4.45M | -10.3M | -8.68M | -11.3M | -5.81M | -3.26M | -2.54M | -2.69M | -1.22M |
| Interest expense | 11.0K | 22.0K | 15.0K | 21.0K | 507.0K | 87.0K | 3.66K | 24.0K | 28.7K |
| Income before tax | 994.0K | -10.6M | -8.90M | -10.5M | -6.95M | -3.51M | -2.69M | -2.87M | -1.43M |
| Income tax | 62.0K | -382.0K | -347.0K | -1.28M | -776.0K | -760.0K | -502.3K | -435.1K | -307.0K |
| Net income | 664.0K | -10.2M | -8.55M | -9.26M | -6.17M | -2.75M | -2.19M | -2.44M | -1.12M |
| Earnings per share, basic | 0.02 | -0.31 | -0.28 | -0.32 | -0.27 | -0.10 | -0.08 | -0.09 | -0.04 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 3.00M | 3.24M | 5.09M | 4.76M | 18.3M | 2.90M | 3.07M | 3.45M | 704.9K | 1.03M |
| Short-term investments | 3.13M | 18.0K | 1.66M | 8.04M | ||||||
| Receivables | 868.0K | 2.87M | 2.87M | 664.0K | 795.0K | 102.0K | 497.3K | 753.0K | 402.0K | 739.7K |
| Inventory | 0 | 478.0K | 771.0K | 1.13M | 0 | -207 | 1 | 0 | 11.4K | |
| Current assets | 7.00M | 8.23M | 11.2M | 17.5M | 20.5M | 3.82M | 3.92M | 5.00M | 1.52M | 1.90M |
| Property, plant and equipment | 838.0K | 328.0K | 375.3K | 295.1K | 353.1K | 438.5K | 551.7K | |||
| Goodwill | 0 | 1.48M | 1.48M | 0 | ||||||
| Total assets | 8.10M | 8.72M | 15.4M | 21.8M | 20.9M | 4.28M | 4.31M | 5.45M | 2.07M | 2.56M |
| Accounts payable | 1.42M | 838.0K | 2.25M | 1.71M | 518.0K | 465.0K | 365.6K | 568.0K | 164.8K | 100.5K |
| Current liabilities | 1.61M | 3.26M | 5.15M | 3.73M | 2.27M | 1.41M | 1.04M | 1.11M | 823.3K | 958.6K |
| Long-term debt | 0 | 1.70M | 0 | 351.8K | ||||||
| Total debt | 98.0K | 232.0K | 338.0K | 288.0K | 231.0K | 2.00M | 158.1K | 221.3K | 660.1K | 576.1K |
| Total liabilities | 1.65M | 3.37M | 5.85M | 4.31M | 2.37M | 3.51M | 1.10M | 1.23M | 1.40M | 1.23M |
| Shareholders' equity | 6.45M | 5.35M | 9.53M | 17.5M | 18.5M | 773.8K | 3.21M | 4.22M | 670.3K | 1.33M |
| Shares outstanding | 39.4M | 33.4M | 30.6M | 28.9M | 23.0M | 27.7M | 27.7M | 27.7M | 27.7M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -2.29M | -9.15M | -5.84M | -10.8M | -5.45M | -1.86M | -458.8K | -2.50M | -492.6K |
| Capital spending | -99.0K | -23.0K | -151.0K | -345.0K | -69.0K | -52.3K | -32.3K | -73.1K | -12.9K |
| Free cash flow | -2.39M | -9.18M | -5.99M | -11.1M | -5.52M | -1.91M | -491.1K | -2.58M | -505.5K |
| Cash from investing | 2.38M | 1.72M | 6.52M | -7.99M | -68.0K | -49.3K | -22.9K | -64.6K | -12.8K |
| Cash from financing | -148.0K | 5.65M | -180.0K | 5.16M | 20.9M | 1.77M | -131.0K | 5.32M | 216.7K |
| Share buybacks | 420 | 1.09K | 200.0K | ||||||
| Change in cash | -238.0K | -1.85M | 328.0K | -13.6M | 15.4M | -175.2K | 2.74M | 2.74M | -323.4K |
Cap table
Built by 6ix from Arecor Therapeutics PLC’s releases · as of Oct 7, 2026
- Common shares
- 45,300,718
- Fully diluted
- 45,300,718
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 45,300,718 | Oct 7, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Oct 7, 2026 | 45,300,718 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Andrew Richards | Non-Executive Chair and Chair of the Nomination Committee · Since at least Apr 13, 2026 |
| Arecor Therapeutics | Singer Capital Markets Advisory LLP · Since at least Jan 6, 2026 |
| David Ellam | Chief Financial Officer and Executive Director · Since at least Oct 15, 2026 |
| David Gerring | Chief Development Officer · Since at least May 21, 2026 |
| Jan Jezek | Chief Scientific Officer · Since at least Oct 15, 2026 |
| Jeremy Morgan | Non-Executive Director and Chair of the Remuneration Committee · Since at least Jun 2, 2025 |
| Phil Davies | Singer Capital Markets Advisory LLP · Since at least Apr 28, 2026 |
| Sam Fazeli | Non-Executive Director · Since at least Jun 2, 2025 |
| Sarah Howell | Chief Executive Officer and Executive Director · Since at least Oct 15, 2026 |
| Simon Ormiston | Non-Executive Director and Chair of the Audit & Risk Committee · Since at least Sep 29, 2025 |
Log in to ask 6ix AI your own questions about Arecor Therapeutics PLC.